hsa-mir-633: Hsa-mir-633 is a microRNA that has been identified as a potential regulator of GC resistance in pediatric acute lymphoblastic leukemia (ALL) [PMC6069764]. It is one of six miRNAs, including hsa-miR-221-3p, hsa-miR-550a-3p, hsa-miR-638, hsa-miR-124-5p, and hsa-miR-15b-3p, that have no retrieved targets after filtering [PMC6069764]. Hsa-mir-633 has been found to functionally correlate with circ_0008896 and up-regulating its level using hsa-mir-633 mimics [PMC8973975]. Bioinformatics analysis using TargetScan has identified CDC20B 3ʹUTR as a potential binding site for hsa-mir-633 [PMC8973975]. Hsa_circ_0008896, which is highly expressed in atherosclerosis models, increases the expression of CDC20B by binding to hsa-mir-633 [PMC8973975]. The role of hsa_circ_0008896 in the proliferation, migration and invasion of VSMCs (vascular smooth muscle cells) has been identified and suggests that both hsa_mir_633 and CDC20B could be potential therapeutic targets [PMC8973975]. Luciferase reporter plasmids have confirmed the direct binding between hsa_mir_633 and the 3ʹUTR of CDC20B [PMC8973975]. Additionally, transwell assay results have shown that inhibiting hsa_mir_633 can reverse the decreased migration and invasion abilities caused by circ_0008896 knockdown in VSMCs [PMC8973975]. The binding between circ_0008896 and hsa_mir_633 has been confirmed through luciferase reporter plasmids [PMC8973975]. The expression level of CDC20B is tightly controlled by hsa_mir_633 [PMC8973975]. The downstream effects of circ_0008896 and hsa_mir_633 on CDC20B have been confirmed through functional assays and down-regulation of CDC20B using si-CDC20B [PMC8973975]. In atherosclerosis models, the level of hsa_mir_633 is decreased [PMC8973975].